"1.Date of the board of directors resolution:2023/12/07
2.Source of capital increase funds:
Cash capital increase by the issuance of new shares
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
Total monetary value of issuance: The actual total amount raised depends on
actual issue price per share.
Total number of shares issued: 20,000,000 shares.
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:NA
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:NA
7.Par value per share:NTD$10
8.Issue price:
Once the application is approved,the Chairman is authorized by
the Board of Directors for pricing the new shares in accordance with the
stipulations of ”Self-regulation Measures for Underwriters Providing
Guidance to Companies in Raising and Issuing Negotiable Securities” and
other relevant laws and regulations.
9.Number of shares subscribed for by or allocated to employees:
In accordance with Article 267 of the Company Act, reserve 10% of new
shares for subscription by the Company's employees to motivate employees.
10.Number of shares publicly sold:
In accordance with Article 28-1 of Securities and Exchange Act, offer 10%
of new shares put up for underwritten distribution by public subscription.
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:
80% of new shares are subscribed by original shareholders in
proportion respectively to their original shareholding recorded on the
register of shareholders on the record date of cash capital increase.
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:
Odd lots below one share subscribed by original shareholders shall be
rounded up to whole shares by the shareholders themselves within
five day from the suspension of share transfer to the company's stock
transfer agent.
Employees and original shareholders may waive subscription or round-up of
odd lots below one share, and the Chairman is authorized to negotiate with
specific individuals to fulfill the subscription at the issuance price.
13.Rights and obligations of these newly issued shares:
Same as the previously issued common shares.
14.Utilization of the funds from the capital increase:
Repayment of short-term bank loans and enrich working capital
15.Any other matters that need to be specified:
(1)It is proposed that the Chairman of the Board of Directors be authorized
to determine the subscription record date, payment period, and capital
increase record date after the Issuance becomes effective following the
approval by the competent authority.
(2)It is proposed that the Chairman of the Board of Directors be authorized
to determine the important matters of the Issuance, including the source
of funding, allocation of proceeds, financing schedule and expected
potential benefits, and, in case that there are any outstanding matters,
any modification or amendment required by the competent authorities or
due to change of circumstances.
(3)In this case of cash capital increase and issuance of ordinary shares,
if the actual issuance price per share is adjusted due to market
changes, resulting in insufficient funds raised, the difference will be
covered by own funds, bank borrowings or other financing tools;
however, if the funds raised increase, the excess will be used as the
company’s working capital."
Taimed has mentioned multiple times they wanted to explore international cooperation for their first line maintenance therapy drugs "a $10 billion market" but it seems they they haven't been able to get any interest so far as they are now raising money in order to deal with short term loans and increasing operating capital.